Drugs.com - New Drug Approvals

FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy

Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of...

Apr 4, 2025 - 06:05
 0
FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy
Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of...
Read More

Tags:

Previous Article

L’Oreal’s SalonCentric to acquire Concept JP

Next Article

US Government Audits vs. Hacking Away at the Bones & Muscles of the US Government

Related Posts

Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

Alnylam Announces FDA Approval of Amvuttra (vutrisiran)...

Mar 24, 2025  0

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen...

Feb 13, 2025  0

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

FDA Approves Omlyclo (omalizumab-igec), an Interchangea...

Mar 7, 2025  0